Sort   by:  
 Page size 
UnknownRandomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
Not available
S-EPMC4962710 | biostudies-literature
UnknownRisk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study.
Not available
S-EPMC3986384 | biostudies-literature
UnknownDiverging Effects of Adolescent Ethanol Exposure on Tripartite Synaptic Development across Prefrontal Cortex Subregions.
Not available
S-EPMC9561972 | biostudies-literature
UnknownMovement Disorders in Prionopathies: A Systematic Review.
Not available
S-EPMC6925394 | biostudies-literature
UnknownPathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199.
Not available
S-EPMC4178524 | biostudies-literature
UnknownA phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).
Not available
S-EPMC6235144 | biostudies-literature
UnknownChanges in nascent chromatin structure regulate activation of the pro-fibrotic transcriptome and myofibroblast emergence in organ fibrosis.
Not available
S-EPMC10214303 | biostudies-literature
UnknownGut microbiota trajectory in early life may predict development of celiac disease.
Not available
S-EPMC5819212 | biostudies-literature
UnknownPrognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study.
Not available
S-EPMC9400113 | biostudies-literature
UnknownEnhanced RNA-targeting CRISPR-Cas technology in zebrafish.
Not available
S-EPMC11482928 | biostudies-literature
Sort   by:  
 Page size